October 17th 2024
Chris Ryan
Belzupacap sarotalocan produced complete responses in patients with low-grade non–muscle-invasive bladder cancer.
October 17th 2024
Jax DiEugenio
Fred Saad, MD, FRCS, discusses efficacy and safety data for darolutamide plus ADT in metastatic hormone-sensitive prostate cancer.
October 17th 2024
Francine Foss, MD
Dr Foss discusses the significance of the FDA approval of denileukin diftitox for patients with relapsed/refractory CTCL.
October 17th 2024
Courtney Flaherty
Cabozantinib plus atezolizumab did not produce superior OS outcomes vs a second novel hormonal therapy in metastatic castration-resistant prostate cancer.
October 17th 2024
Courtney Flaherty
Ashraf Z. Badros, MBCHB, discusses the use of daratumumab plus lenalidomide as maintenance therapy after transplant in newly diagnosed multiple myeloma.